Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4747643 | 0.90 | FFAR2 (0.44) | FFAR2ALDH1A1SMN1; SMN2GAANPSR1 | |
| SCHEMBL4885880 | 0.82 | CNR1 (0.39) | ALDH1A1SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL3441524 | 0.79 | RECQL (0.45) | FFAR2ALDH1A1SMN1; SMN2GAANPSR1 | |
| SCHEMBL4786438 | 0.78 | CNR1 (0.43) | ALDH1A1LMNAMAPTHDAC1L3MBTL1 | |
| SCHEMBL4897158 | 0.75 | MAPT (0.41) | ALDH1A1NPSR1LMNAMAPT | |
| SCHEMBL4894672 | 0.74 | MAPK14 (0.34) | SMN1; SMN2LMNAMAPTL3MBTL1 | |
| SCHEMBL4892358 | 0.71 | MAPK1 (0.45) | ALDH1A1GAALMNAMAPTL3MBTL1 | |
| SCHEMBL14020621 | 0.70 | KDM4E (0.34) | SMN1; SMN2LMNAMAPT | |
| SCHEMBL4891117 | 0.70 | ENPP2 (0.40) | MAPT | |
| SCHEMBL4896089 | 0.69 | L3MBTL1 (0.46) | ALDH1A1SMN1; SMN2GAANPSR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | claimed |
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | ASTRAZENECA AB (SE) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262064-A1 | Novel Compounds For The Treatment Of GI Disorders 682 | GABRB2, GABRA2, GABBR2 | FFAR2 62/4885ALDH1A1 2271/4885SMN1; SMN2 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.